D Ross Camidge Selected Research

Anaplastic Lymphoma Kinase

9/2022	Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.
1/2022	Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
11/2020	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
1/2019	ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
11/2018	Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
10/2018	Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
1/2018	Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung Cancer.
8/2017	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
1/2017	Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
1/2017	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

D Ross Camidge Research Topics

Disease

105	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 11/2006
71	Neoplasms (Cancer) 01/2022 - 09/2007
39	Lung Neoplasms (Lung Cancer) 07/2022 - 07/2007
22	Disease Progression 06/2022 - 09/2009
15	Brain Neoplasms (Brain Tumor) 01/2022 - 06/2015
14	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 03/2011
13	Neoplasm Metastasis (Metastasis) 06/2022 - 01/2016
9	Fatigue 01/2021 - 09/2009
6	Central Nervous System Diseases (CNS Diseases) 01/2021 - 10/2015
5	Diarrhea 01/2022 - 12/2013
5	Thrombocytopenia (Thrombopenia) 01/2021 - 09/2009
5	Nausea 01/2021 - 08/2007
4	Vomiting 01/2021 - 08/2007
4	Dyspnea (Shortness of Breath) 01/2021 - 06/2013
4	Sarcoma (Soft Tissue Sarcoma) 01/2019 - 09/2012
4	Adenocarcinoma 01/2018 - 11/2008
3	Pneumonia (Pneumonitis) 08/2020 - 12/2016
3	Neutropenia 01/2019 - 09/2009
3	Adenocarcinoma of Lung 01/2018 - 02/2015
2	Thymoma (Thymic Carcinoma) 07/2022 - 01/2017
2	Exanthema (Rash) 01/2022 - 11/2017
2	Constipation 01/2021 - 04/2011
2	Interstitial Lung Diseases (Interstitial Lung Disease) 08/2020 - 04/2016
2	Chronic Renal Insufficiency 01/2019 - 03/2014
2	Neuroblastoma 01/2016 - 02/2015
2	Alopecia (Baldness) 06/2013 - 09/2009
1	Prostatic Neoplasms (Prostate Cancer) 07/2022
1	Neurologic Manifestations (Neurological Manifestations) 01/2022

Drug/Important Bio-Agent (IBA)

54	CrizotinibIBA 06/2022 - 10/2010
30	Anaplastic Lymphoma KinaseIBA 09/2022 - 12/2009
28	Tyrosine Kinase InhibitorsIBA 09/2022 - 07/2010
21	ErbB Receptors (EGF Receptor)IBA 01/2022 - 11/2008
14	brigatinibIBA 09/2022 - 08/2017
12	Biomarkers (Surrogate Marker)IBA 07/2022 - 03/2011
12	Pharmaceutical PreparationsIBA 01/2022 - 04/2011
11	alectinibIBA 09/2022 - 02/2016
10	Phosphotransferases (Kinase)IBA 01/2018 - 12/2010
7	Carboplatin (JM8)FDA LinkGeneric 01/2019 - 08/2008
7	Erlotinib Hydrochloride (CP 358,774)FDA Link 11/2017 - 09/2011
6	Pemetrexed (MTA)FDA Link 10/2015 - 04/2011
5	Immune Checkpoint InhibitorsIBA 11/2021 - 01/2019
5	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2018 - 11/2014
5	Paclitaxel (Taxol)FDA LinkGeneric 10/2014 - 08/2008
5	Monoclonal AntibodiesIBA 05/2014 - 08/2008
4	Immunoconjugates (Immunoconjugate)IBA 11/2021 - 08/2017
4	osimertinibIBA 01/2021 - 12/2016
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 10/2016
4	Proteins (Proteins, Gene)FDA Link 01/2019 - 03/2011
4	rociletinibIBA 11/2018 - 04/2015
4	PlatinumIBA 01/2018 - 06/2013
3	navitoclaxIBA 01/2021 - 03/2011
3	Circulating Tumor DNAIBA 01/2021 - 01/2019
3	NivolumabIBA 01/2021 - 01/2020
3	CreatinineIBA 01/2019 - 09/2011
3	lorlatinibIBA 01/2019 - 12/2018
3	Sunitinib (Sutent)FDA Link 10/2018 - 02/2013
3	AfatinibIBA 01/2018 - 09/2014
3	Transaminases (Aminotransferases)IBA 01/2017 - 06/2013
3	RamucirumabIBA 03/2015 - 02/2010
3	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 02/2010 - 07/2007
2	Cell-Free Nucleic AcidsIBA 01/2022 - 11/2018
2	Proto-Oncogene Proteins c-metIBA 01/2022 - 01/2017
2	human ERBB2 proteinIBA 08/2020 - 02/2015
2	Alanine Transaminase (SGPT)IBA 01/2020 - 10/2012
2	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2020 - 05/2012
2	Messenger RNA (mRNA)IBA 01/2019 - 06/2014
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2019 - 01/2017
2	LigandsIBA 01/2019 - 05/2014
2	ponatinibIBA 01/2019 - 06/2014
2	Gefitinib (Iressa)FDA Link 11/2017 - 09/2014
2	Cetuximab (Erbitux)FDA Link 11/2017 - 09/2014
2	sacituzumab govitecanIBA 10/2017 - 08/2017
2	ceritinibIBA 04/2016 - 03/2014
2	dacomitinibIBA 01/2016 - 04/2014
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2015 - 02/2010
2	mapatumumabIBA 05/2014 - 09/2009
2	Testosterone (Sustanon)FDA Link 07/2013 - 11/2012
2	Peptides (Polypeptides)IBA 06/2012 - 03/2011
2	big gastrinIBA 06/2012 - 03/2011
2	Immunoglobulin G (IgG)IBA 02/2012 - 02/2010
2	CaspasesIBA 11/2010 - 09/2010
2	Insulin-Like PeptidesIBA 07/2009 - 08/2008
1	monalizumabIBA 10/2022
1	durvalumabIBA 10/2022
1	entrectinibIBA 06/2022
1	amivantamab-vmjwIBA 01/2022
1	Trastuzumab (Herceptin)FDA Link 01/2022
1	pralsetinibIBA 01/2022
1	SteroidsIBA 01/2022
1	Lipase (Acid Lipase)FDA Link 11/2021
1	telisotuzumab vedotinIBA 11/2021
1	Glycoproteins (Glycoprotein)IBA 11/2021

Therapy/Procedure

55	Therapeutics 01/2022 - 11/2006
22	Drug Therapy (Chemotherapy) 10/2020 - 07/2007
17	Radiotherapy 01/2022 - 11/2006
6	Immunotherapy 07/2021 - 12/2017
1	Chemoradiotherapy 10/2022
1	Castration 07/2022
1	Cranial Irradiation 01/2022
1	Neoadjuvant Therapy 07/2021